Hansa Biopharma publishes Annual Report 2020
Lund, Sweden April 8, 2021 Hansa Biopharma AB “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of the Annual Report 2020 Søren Tulstrup, President and CEO of Hansa Biopharma, comments:“2020 was a highly successful and transformative year for Hansa Biopharm – a year where we saw significant progress across all areas important to building a leading biopharmaceutical company: Pipeline development, medical and commercial operations and organizational development. Most notably, we received conditional